skip to main content
Idioma:
Resultados 1 2 3 4 5 next page
Mostrar Somente
Refinado por: Base de dados/Biblioteca: ScienceDirect remover assunto: Treatment Outcome remover
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials
Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials
Material Type:
Artigo 		Adicionar ao Meu Espaço

Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials

Reich, Kristian, Prof ; Papp, Kim A, MD ; Blauvelt, Andrew, MD ; Tyring, Stephen K, Prof ; Sinclair, Rodney, Prof ; Thaçi, Diamant, Prof ; Nograles, Kristine, MD ; Mehta, Anish, BA ; Cichanowitz, Nicole, MSJ ; Li, Qing, PhD ; Liu, Kenneth, PhD ; La Rosa, Carmen, MD ; Green, Stuart, MD ; Kimball, Alexa B, Prof

The Lancet (British edition), 2017-07, Vol.390 (10091), p.276-288 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
2
Treatment of hidradenitis suppurativa with biologic medications
Treatment of hidradenitis suppurativa with biologic medications
Material Type:
Artigo 		Adicionar ao Meu Espaço

Treatment of hidradenitis suppurativa with biologic medications

Lee, Robert A., MD, PhD ; Eisen, Daniel B., MD

Journal of the American Academy of Dermatology, 2015-11, Vol.73 (5), p.S82-S88 [Periódico revisado por pares]

United States: Elsevier Inc

Texto completo disponível

Citações Citado por
3
Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3)
Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3)
Material Type:
Artigo 		Adicionar ao Meu Espaço

Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3)

Blauvelt, Andrew ; Gooderham, Melinda ; Iversen, Lars ; Ball, Susan ; Zhang, Lu ; Agada, Noah O. ; Reich, Kristian

Journal of the American Academy of Dermatology, 2017-11, Vol.77 (5), p.855-862 [Periódico revisado por pares]

United States: Elsevier Inc

Texto completo disponível

Citações Citado por
4
Comparative efficacy of biologics and oral agents in palmoplantar psoriasis and palmoplantar pustulosis: A systematic review and network meta-analysis of randomized clinical trials
Comparative efficacy of biologics and oral agents in palmoplantar psoriasis and palmoplantar pustulosis: A systematic review and network meta-analysis of randomized clinical trials
Material Type:
Artigo 		Adicionar ao Meu Espaço

Comparative efficacy of biologics and oral agents in palmoplantar psoriasis and palmoplantar pustulosis: A systematic review and network meta-analysis of randomized clinical trials

Spencer, Riley K. ; Jin, Joy Q. ; Elhage, Kareem G. ; Davis, Mitchell S. ; Hakimi, Marwa ; Bhutani, Tina ; Liao, Wilson

Journal of the American Academy of Dermatology, 2023-08, Vol.89 (2), p.423-425 [Periódico revisado por pares]

United States: Elsevier Inc

Texto completo disponível

Citações Citado por
5
Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial
Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial

Porter, Duncan, Dr ; van Melckebeke, Jurgen, BSc ; Dale, James, PhD ; Messow, C Martina, PhD ; McConnachie, Alexander, PhD ; Walker, Andrew, PhD ; Munro, Robin, MRCP ; McLaren, John, MRCP ; McRorie, Euan, FRCP ; Packham, Jon, DM ; Buckley, Christopher D, Prof ; Harvie, John, FRCP ; Taylor, Peter, Prof ; Choy, Ernest, Prof ; Pitzalis, Costantino, Prof ; McInnes, Iain B, Prof

The Lancet (British edition), 2016-07, Vol.388 (10041), p.239-247 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
6
Comparative effectiveness of targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis
Comparative effectiveness of targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis
Material Type:
Artigo 		Adicionar ao Meu Espaço

Comparative effectiveness of targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis

Loos, Anne M. ; Liu, Shanshan ; Segel, Celia ; Ollendorf, Daniel A. ; Pearson, Steven D. ; Linder, Jeffrey A.

Journal of the American Academy of Dermatology, 2018-07, Vol.79 (1), p.135-144.e7 [Periódico revisado por pares]

United States: Elsevier Inc

Texto completo disponível

Citações Citado por
7
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials
Material Type:
Artigo 		Adicionar ao Meu Espaço

Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials

Griffiths, Christopher E M, Prof ; Reich, Kristian, Prof ; Lebwohl, Mark, Prof ; van de Kerkhof, Peter, Prof ; Paul, Carle, Prof ; Menter, Alan, MD ; Cameron, Gregory S, PhD ; Erickson, Janelle, PhD ; Zhang, Lu, MS ; Secrest, Roberta J, PhD ; Ball, Susan, PhD ; Braun, Daniel K, MD ; Osuntokun, Olawale O, MD ; Heffernan, Michael P, MD ; Nickoloff, Brian J, MD ; Papp, Kim, MD

The Lancet (British edition), 2015-08, Vol.386 (9993), p.541-551 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
8
Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR])
Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR])
Material Type:
Artigo 		Adicionar ao Meu Espaço

Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR])

Strober, Bruce E., MD, PhD ; Bissonnette, Robert, MD ; Fiorentino, David, MD, PhD ; Kimball, Alexa B., MPH, MD ; Naldi, Luigi, MD ; Shear, Neil H., MD ; Goyal, Kavitha, MD ; Fakharzadeh, Steven, MD, PhD ; Calabro, Stephen, MS ; Langholff, Wayne, PhD ; You, Yin, MS ; Galindo, Claudia, MD ; Lee, Seina, MS, PharmD ; Lebwohl, Mark G., MD

Journal of the American Academy of Dermatology, 2016-05, Vol.74 (5), p.851-861.e4 [Periódico revisado por pares]

United States: Elsevier Inc

Texto completo disponível

Citações Citado por
9
Etanercept reduces anxiety and depression in psoriasis patients, and sustained depression correlates with reduced therapeutic response to etanercept
Etanercept reduces anxiety and depression in psoriasis patients, and sustained depression correlates with reduced therapeutic response to etanercept
Material Type:
Artigo 		Adicionar ao Meu Espaço

Etanercept reduces anxiety and depression in psoriasis patients, and sustained depression correlates with reduced therapeutic response to etanercept

Yang, A. ; Xin, X. ; Yang, W. ; Li, M. ; Li, L. ; Liu, X.

Annales de dermatologie et de vénéréologie, 2019-05, Vol.146 (5), p.363-371 [Periódico revisado por pares]

France: Elsevier Masson SAS

Texto completo disponível

Citações Citado por
10
The role of C-reactive protein as a predictor of treatment response in patients with ankylosing spondylitis
The role of C-reactive protein as a predictor of treatment response in patients with ankylosing spondylitis
Material Type:
Artigo 		Adicionar ao Meu Espaço

The role of C-reactive protein as a predictor of treatment response in patients with ankylosing spondylitis

Baraliakos, Xenofon ; Szumski, Annette ; Koenig, Andrew S. ; Jones, Heather

Seminars in arthritis and rheumatism, 2019-06, Vol.48 (6), p.997-1004 [Periódico revisado por pares]

United States: Elsevier Inc

Texto completo disponível

Citações Citado por
Resultados 1 2 3 4 5 next page

Personalize Seus Resultados

  1. Editar

Refine Search Results

Expandir Meus Resultados

  1.   

Mostrar Somente

  1. Recursos Online (258)
  2. Revistas revisadas por pares (256)

Refinar Meus Resultados

Tipo de Recurso 

  1. Artigos  (268)
  2. magazinearticle  (1)
  3. Mais opções open sub menu

Data de Publicação 

De até
Refinar
  1. Antes de2003  (11)
  2. 2003Até2007  (50)
  3. 2008Até2012  (95)
  4. 2013Até2018  (83)
  5. Após 2018  (31)
  6. Mais opções open sub menu

Idioma 

  1. Inglês  (248)
  2. Japonês  (26)
  3. Francês  (16)
  4. Espanhol  (16)
  5. Português  (4)
  6. Russo  (1)
  7. Mais opções open sub menu

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.